Background: Gestational diabetes mellitus (GDM) is carbohydrate intolerance first recognised throughout being pregnant and related to problems for moms and infants. Probiotics are naturally occurring micro-organisms, which when ingested in satisfactory quantities, could confer well being advantages. Proof of the function of probiotics as therapy for GDM is proscribed.
Goals: To guage the security and effectiveness of probiotics in treating girls with GDM on maternal and toddler outcomes.
Search strategies: We searched the Cochrane Being pregnant and Childbirth’s Trials Register ClinicalTrials.gov, WHO Worldwide Scientific Trials Registry Platform (ICTRP) (24 July 2019), and reference lists of retrieved research.
Choice standards: Randomised managed trials (RCTs) evaluating using probiotics versus placebo/commonplace take care of the therapy of GDM.
Information assortment and evaluation: Two overview authors independently assessed research eligibility, extracted knowledge, checked knowledge accuracy, and assessed danger of bias of included trials. The knowledge of proof for chosen maternal and toddler/baby outcomes was assessed utilizing GRADE.
Foremost outcomes: 9 RCTs (695 pregnant girls with GDM) evaluating probiotics versus placebo had been recognized. The general danger of bias within the 9 RCTs was low to unclear and the proof was downgraded for imprecision as a result of small numbers of ladies taking part within the trials. The trials had been carried out in hospitals and universities in Iran (seven trials), Thailand (one trial) and Eire (one trial). All trials in contrast probiotics with placebo. Maternal outcomes We’re unsure if probiotics have any impact in contrast with placebo on hypertensive problems of being pregnant, (danger ratio (RR) 1.50, 95% confidence interval (CI) 0.64 to three.53; individuals = 256; research = 3; low-certainty proof) and mode of beginning as caesareans (common RR 0.64, 95% CI 0.30 to 1.35; individuals = 267; research = 3; low-certainty proof) as a result of the knowledge of proof is low and the 95% CIs span potential profit and potential hurt. No trials reported major outcomes of: mode of beginning as vaginal/assisted and subsequent improvement of sort 2 diabetes. We’re unsure if probiotics have any impact in contrast with placebo on induction of labour (RR 1.33, 95% CI 0.74 to 2.37; individuals = 127; research = 1; very low-certainty proof). For different secondary maternal outcomes, we’re unsure if there are variations between probiotics and placebo for: postpartum haemorrhage; weight acquire throughout being pregnant intervention and whole gestational weight acquire; fasting plasma glucose and want for further pharmacotherapy (insulin). Probiotics could also be related to a slight discount in triglycerides and whole ldl cholesterol.
In probiotics in contrast with placebo, there was proof of discount in markers for insulin resistance (HOMA-IR) and HOMA-B; and insulin secretion. There was additionally a rise in quantitative insulin sensitivity test index (QUICKI). Probiotics had been related to minor advantages in related bio-markers with proof of a discount in inflammatory markers high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and marker of oxidative stress malondialdehyde; and a rise in antioxidant whole glutathione, however we’re unsure if there may be any distinction in whole antioxidant capability. No trials reported secondary outcomes: perineal trauma, postnatal weight retention or return to pre-pregnancy weight and postnatal melancholy.
Toddler/baby/grownup outcomes We’re unsure if probiotics have any impact, in contrast with placebo, on the danger of large-for-gestational-age infants (RR 0.73, 95% CI 0.35 to 1.52; individuals = 174; research = 2; low-certainty proof) or toddler hypoglycaemia (RR 0.85, 95% CI 0.39 to 1.84; individuals = 177; research = 3; low-certainty proof) as a result of the knowledge of proof is low and the 95% CIs span potential profit and potential hurt. No trials reported major outcomes of: perinatal (fetal/neonatal) mortality; or neurosensory incapacity. For different secondary outcomes, we’re unsure if there may be any distinction between probiotics and placebo in gestational age at beginning, preterm beginning, macrosomia, birthweight, head circumference, size, toddler hypoglycaemia, and neonatal intensive care unit (NICU) admissions. There was proof of a discount in toddler hyperbilirubinaemia with probiotics in contrast with placebo. No trials reported secondary outcomes: toddler adiposity, and later childhood adiposity. There have been no adversarial occasions reported by any of the trials.
Authors’ conclusions: Low-certainty proof means we’re not sure if there may be any distinction between probiotic and placebo teams in maternal hypertensive problems of being pregnant, caesareans; and large-for-gestational-age infants. There have been no adversarial occasions reported by the trials. Because of the variability of probiotics used and small pattern sizes of trials, proof from this overview has restricted means to tell observe. Nicely-designed adequately-powered trials are wanted to establish whether or not probiotics could enhance maternal blood glucose ranges and/or toddler/baby/grownup outcomes; and whether or not they can be utilized to deal with GDM.
Retrospective screening of high-resolution mass spectrometry archived digital samples can enhance environmental danger evaluation of rising contaminants: A case research on antifungal azoles.
Environmental danger evaluation related to aquatic and terrestrial contamination is usually based mostly on predicted or measured environmental concentrations of a restricted checklist of chemical substances in a restricted variety of environmental compartments. Excessive decision mass spectrometry (HRMS) can present a extra complete image of publicity to dangerous chemical substances, significantly by means of the retrospective evaluation of digitally saved HRMS knowledge. Utilizing this technique, our research characterised the contamination of varied environmental compartments together with 154 floor water, 46 city effluent, 67 sediment, 15 soil, 34 groundwater, 24 biomovie, 41 gammarid and 49 fish samples at 95 websites broadly distributed over the Swiss Plateau.
As a proof-of-concept, we targeted our investigation on antifungal azoles, a category of chemical substances of rising concern on account of their endocrine disrupting results on aquatic organisms and people. Our outcomes demonstrated the prevalence of antifungal azoles and a few of their (bio)transformation merchandise in all of the analyzed compartments (0.1-100 ng/L or ng/g d.w.). Comparability of precise and predicted concentrations confirmed the partial suitability of degree 1 fugacity modelling in predicting the publicity to azoles. Danger quotient calculations moreover revealed danger of publicity particularly if a number of the investigated rivers and streams are used for consuming water manufacturing.
Ferritin light chain antibody |
10-1569 |
Fitzgerald |
1 mg |
EUR 418.8 |
Description: Mouse monoclonal Ferritin light chain antibody |
Ferritin light chain antibody |
10-1570 |
Fitzgerald |
1 mg |
EUR 418.8 |
Description: Mouse monoclonal Ferritin light chain antibody |
Lambda Light chain Antibody |
43108-100ul |
SAB |
100ul |
EUR 302.4 |
Kappa Light chain Antibody |
46588-100ul |
SAB |
100ul |
EUR 302.4 |
Ferritin Light Chain Antibody |
49643-100ul |
SAB |
100ul |
EUR 399.6 |
Ferritin Light Chain Antibody |
49643-50ul |
SAB |
50ul |
EUR 286.8 |
Ferritin Light Chain antibody |
10R-8606 |
Fitzgerald |
100 ul |
EUR 471.6 |
Description: Mouse monoclonal Ferritin Light Chain antibody |
IgG light chain Antibody |
abx140241-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
lambda light chain Antibody |
abx034778-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
lambda light chain Antibody |
abx034778-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
kappa light chain Antibody |
abx025345-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
kappa light chain Antibody |
abx025345-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Acrosin light chain Antibody |
abx432275-200ul |
Abbexa |
200 ul |
EUR 343.2 |
|
Ferritin Light Chain Antibody |
DF6604 |
Affbiotech |
200ul |
EUR 420 |
Kappa light chain Antibody |
DF13703 |
Affbiotech |
100ul |
EUR 420 |
Lambda Light chain Antibody |
DF14068 |
Affbiotech |
100ul |
EUR 420 |
Lambda Light Chain Antibody |
V8873-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody |
V8873-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody |
V8873SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9030-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9030-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9030IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9030SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9031-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9031-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9031IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V9031SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2624-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2624-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2624IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2624SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3135-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3135-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3135IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3135SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3148-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3148-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3148IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3148SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3302-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3302-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3302SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3591-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3591-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3591IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3591SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3592-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3592-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3592IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3592SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3606-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3606-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3606IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3606SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3681-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3681-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3681IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3681SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3713-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3713-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3713IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3713SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3846-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3846-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3846SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3855-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3855-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V3855SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7052-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7052-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7052IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7052SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7424-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7424-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7424IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V7424SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2145-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2145-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2145IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2145SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2146-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2146-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2146CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2146IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2146SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2150-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2150-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2150CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2150IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Kappa Light Chain Antibody |
V2150SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
F5(Coagulation factor V light chain) Conjugated Antibody |
C47757 |
SAB |
100ul |
EUR 476.4 |
Kappa Light Chain |
10R-8329 |
Fitzgerald |
100 ug |
EUR 318 |
Description: Mouse monoclonal Kappa Light Chain antibody |
Human Factor X Light Chain AssayLite Antibody (FITC Conjugate) |
72215-05141 |
AssayPro |
150 ug |
EUR 513.6 |
Rabbit Kappa light chain antibody |
70R-10679 |
Fitzgerald |
1 ml |
EUR 447.6 |
Description: Rabbit polyclonal Kappa light chain antibody |
Rabbit Lambda light chain antibody |
70R-10680 |
Fitzgerald |
1 ml |
EUR 417.6 |
Description: Rabbit polyclonal Lambda light chain antibody |
Myosin Light Chain 1 antibody |
10-M22A |
Fitzgerald |
1 mg |
EUR 330 |
Description: Mouse monoclonal Myosin Light Chain 1 antibody |
Ferritin light chain Monoclonal Antibody |
42045-100ul |
SAB |
100ul |
EUR 399.6 |
igg light chain Polyclonal Antibody |
42162-100ul |
SAB |
100ul |
EUR 399.6 |
Ferritin light chain Polyclonal Antibody |
42538-100ul |
SAB |
100ul |
EUR 399.6 |
Myosin Light Chain 2 antibody |
70R-37593 |
Fitzgerald |
100 ug |
EUR 327.6 |
Description: Rabbit Polyclonal Myosin Light Chain 2 antibody |
Human Iambda light chain Antibody |
48057-100ul |
SAB |
100ul |
EUR 399.6 |
Human Iambda light chain Antibody |
48057-50ul |
SAB |
50ul |
EUR 286.8 |
Myosin light chain kinase Antibody |
48846-100ul |
SAB |
100ul |
EUR 399.6 |
Myosin light chain kinase Antibody |
48846-50ul |
SAB |
50ul |
EUR 286.8 |
Myosin Light Chain 2 Antibody |
49023-100ul |
SAB |
100ul |
EUR 399.6 |
Myosin Light Chain 2 Antibody |
49023-50ul |
SAB |
50ul |
EUR 286.8 |
Human Ferritin Light Chain Antibody |
32889-05111 |
AssayPro |
150 ug |
EUR 313.2 |
Human Dynein light chain Antibody |
33041-05111 |
AssayPro |
150 ug |
EUR 313.2 |
Myosin Light Chain 2 antibody |
20R-1971 |
Fitzgerald |
50 ug |
EUR 337.2 |
Description: Rabbit polyclonal Myosin Light Chain 2 antibody |
Myosin Light Chain 2 antibody |
20R-2327 |
Fitzgerald |
50 ug |
EUR 337.2 |
Description: Rabbit polyclonal Myosin Light Chain 2 antibody |
IgG (Light Chain Specific) Antibody |
20-abx159553 |
Abbexa |
|
|
|
Ig kappa Light Chain Antibody |
20-abx137077 |
Abbexa |
|
|
|
Ig lambda Light Chain Antibody |
20-abx137078 |
Abbexa |
|
|
|
Myosin Light Chain 4 Antibody |
20-abx137474 |
Abbexa |
-
EUR 844.80
-
EUR 393.60
-
EUR 276.00
|
|
|
Ferritin light chain Antibody (Biotin) |
20-abx105411 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin light chain Antibody (Biotin) |
20-abx105412 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin Light Chain (FTL) Antibody |
20-abx001467 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Ferritin light chain Antibody (HRP) |
20-abx108249 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin light chain Antibody (HRP) |
20-abx108250 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin Light Chain (FTL) Antibody |
20-abx109781 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin Light Chain (FTL) Antibody |
20-abx109782 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin light chain Antibody (FITC) |
20-abx106830 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin light chain Antibody (FITC) |
20-abx106831 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ferritin Light Chain (FTL) Antibody |
abx016118-100ug |
Abbexa |
100 ug |
EUR 493.2 |
|
The case research clearly reveals that the retrospective evaluation of HRMS/MS knowledge can enhance the present information on publicity and the associated dangers to chemical substances of rising concern and may be successfully employed sooner or later for such functions. Innovation diffusion principle proposed that adopters-whether people or organizations-sometimes reinvent an innovation as they acquire expertise utilizing it. Reinvention can improve (or impede) the probability of an IS innovation’s acceptance and additional diffusion. This paper stories on a case research of BioSense, an interorganizational system that was designed as an early detection software for bio-terror assaults and subsequently modified to raised serve this want in addition to to function as a public well being system for pinpointing geographic clusters of harmful/acute illness outbreaks. By inspecting the interaction among the many political and organizational dynamics and technical properties of the BioSense system, we make clear processes affecting reinvention in an interorganizational context.
Welcome to our blog!